THE USE OF ERYTROCYTE-APHERESIS FOR THE TREATMENT OF HEREDITARY HEMOCHROMATOSIS: OUR EXPERIENCE.
(Abstract release date: 05/19/16)
EHA Library. Bruzzese A. 06/09/16; 133131; E1582
Dr. Antonella Bruzzese
Contributions
Contributions
Abstract
Abstract: E1582
Type: Eposter Presentation
Background
The erytrocyte- apheresis has proved advantageous for the treatment of patients with hereditary hemochromatosis (HH) and iron overload, rather than the traditional 'bloodletting', allowing a less frequent treatment and more personalized. It would lead to a greater decrease in serum ferritin for single treatment procedure, without a major reduction in Hepcidin. This may be clinically relevant, being able to prevent an increase in intestinal iron uptake and a vicious circle resulting in the need for frequent treatments. The accessibility to the method, however, is hindered by the lack of access to the extracorporeal circulation, required to achieve it.
Aims
To facilitate access of the erytrocyte- apheresis to a population of subjects suffering from hemocromatosis, we made available the expertise in the field of extracorporeal circulation, the staff of a hemodialysis center. After an activity of about 10 years, we have conducted a retrospective observational study, comparing with some parameters, subjects undergoing erytrocyte- apheresis with a control group that continued to be subjected to bloodletting.
Methods
Over a period of 10 years, we treated, 37 patients with hematological diagnosis of hereditary hemochromatosis with erytrocyte- apheresis. We have selected among the patients with the same diagnosis that continued to be subjected to bloodletting, a 'control' group of 38 patients with similar nosographic characteristics. The retrospective assessment has been focused on the following parameters: hematocrit, levels of blood ferritin, number of treatment procedures, length of intervals between a treatment and another. We also evaluated the costs of treatment.
Results
The mean number of treatment / year procedures was significantly lower for patients treated with erytrocyte- apheresis compared to those treated with bloodletting. The average time interval between two consecutive treatments is a result of 2.3 times longer for the erytrocyte- apheresis compared to bloodletting. The interval between two consecutive procedures of erytrocyte- apheresis has shown a tendency to a progressive increase in the longer time interval of time between a drain and the other. The average annual cost of treatment with erytrocyte- apheresis was about twice compared to those of bloodletting.
Conclusion
The erytrocyte- apheresis reduced, in our experience, significantly the number of treatment procedures rather than the bloodletting. We believe that, where there is easily available the acces to the extracorporeal circulation for cell separation, the erytrocyte- apheresis procedure could become the treatment of choice for patients suffering from hemochromatosis.
Session topic: E-poster
Keyword(s): Apheresis
Type: Eposter Presentation
Background
The erytrocyte- apheresis has proved advantageous for the treatment of patients with hereditary hemochromatosis (HH) and iron overload, rather than the traditional 'bloodletting', allowing a less frequent treatment and more personalized. It would lead to a greater decrease in serum ferritin for single treatment procedure, without a major reduction in Hepcidin. This may be clinically relevant, being able to prevent an increase in intestinal iron uptake and a vicious circle resulting in the need for frequent treatments. The accessibility to the method, however, is hindered by the lack of access to the extracorporeal circulation, required to achieve it.
Aims
To facilitate access of the erytrocyte- apheresis to a population of subjects suffering from hemocromatosis, we made available the expertise in the field of extracorporeal circulation, the staff of a hemodialysis center. After an activity of about 10 years, we have conducted a retrospective observational study, comparing with some parameters, subjects undergoing erytrocyte- apheresis with a control group that continued to be subjected to bloodletting.
Methods
Over a period of 10 years, we treated, 37 patients with hematological diagnosis of hereditary hemochromatosis with erytrocyte- apheresis. We have selected among the patients with the same diagnosis that continued to be subjected to bloodletting, a 'control' group of 38 patients with similar nosographic characteristics. The retrospective assessment has been focused on the following parameters: hematocrit, levels of blood ferritin, number of treatment procedures, length of intervals between a treatment and another. We also evaluated the costs of treatment.
Results
The mean number of treatment / year procedures was significantly lower for patients treated with erytrocyte- apheresis compared to those treated with bloodletting. The average time interval between two consecutive treatments is a result of 2.3 times longer for the erytrocyte- apheresis compared to bloodletting. The interval between two consecutive procedures of erytrocyte- apheresis has shown a tendency to a progressive increase in the longer time interval of time between a drain and the other. The average annual cost of treatment with erytrocyte- apheresis was about twice compared to those of bloodletting.
Conclusion
The erytrocyte- apheresis reduced, in our experience, significantly the number of treatment procedures rather than the bloodletting. We believe that, where there is easily available the acces to the extracorporeal circulation for cell separation, the erytrocyte- apheresis procedure could become the treatment of choice for patients suffering from hemochromatosis.
Session topic: E-poster
Keyword(s): Apheresis
Abstract: E1582
Type: Eposter Presentation
Background
The erytrocyte- apheresis has proved advantageous for the treatment of patients with hereditary hemochromatosis (HH) and iron overload, rather than the traditional 'bloodletting', allowing a less frequent treatment and more personalized. It would lead to a greater decrease in serum ferritin for single treatment procedure, without a major reduction in Hepcidin. This may be clinically relevant, being able to prevent an increase in intestinal iron uptake and a vicious circle resulting in the need for frequent treatments. The accessibility to the method, however, is hindered by the lack of access to the extracorporeal circulation, required to achieve it.
Aims
To facilitate access of the erytrocyte- apheresis to a population of subjects suffering from hemocromatosis, we made available the expertise in the field of extracorporeal circulation, the staff of a hemodialysis center. After an activity of about 10 years, we have conducted a retrospective observational study, comparing with some parameters, subjects undergoing erytrocyte- apheresis with a control group that continued to be subjected to bloodletting.
Methods
Over a period of 10 years, we treated, 37 patients with hematological diagnosis of hereditary hemochromatosis with erytrocyte- apheresis. We have selected among the patients with the same diagnosis that continued to be subjected to bloodletting, a 'control' group of 38 patients with similar nosographic characteristics. The retrospective assessment has been focused on the following parameters: hematocrit, levels of blood ferritin, number of treatment procedures, length of intervals between a treatment and another. We also evaluated the costs of treatment.
Results
The mean number of treatment / year procedures was significantly lower for patients treated with erytrocyte- apheresis compared to those treated with bloodletting. The average time interval between two consecutive treatments is a result of 2.3 times longer for the erytrocyte- apheresis compared to bloodletting. The interval between two consecutive procedures of erytrocyte- apheresis has shown a tendency to a progressive increase in the longer time interval of time between a drain and the other. The average annual cost of treatment with erytrocyte- apheresis was about twice compared to those of bloodletting.
Conclusion
The erytrocyte- apheresis reduced, in our experience, significantly the number of treatment procedures rather than the bloodletting. We believe that, where there is easily available the acces to the extracorporeal circulation for cell separation, the erytrocyte- apheresis procedure could become the treatment of choice for patients suffering from hemochromatosis.
Session topic: E-poster
Keyword(s): Apheresis
Type: Eposter Presentation
Background
The erytrocyte- apheresis has proved advantageous for the treatment of patients with hereditary hemochromatosis (HH) and iron overload, rather than the traditional 'bloodletting', allowing a less frequent treatment and more personalized. It would lead to a greater decrease in serum ferritin for single treatment procedure, without a major reduction in Hepcidin. This may be clinically relevant, being able to prevent an increase in intestinal iron uptake and a vicious circle resulting in the need for frequent treatments. The accessibility to the method, however, is hindered by the lack of access to the extracorporeal circulation, required to achieve it.
Aims
To facilitate access of the erytrocyte- apheresis to a population of subjects suffering from hemocromatosis, we made available the expertise in the field of extracorporeal circulation, the staff of a hemodialysis center. After an activity of about 10 years, we have conducted a retrospective observational study, comparing with some parameters, subjects undergoing erytrocyte- apheresis with a control group that continued to be subjected to bloodletting.
Methods
Over a period of 10 years, we treated, 37 patients with hematological diagnosis of hereditary hemochromatosis with erytrocyte- apheresis. We have selected among the patients with the same diagnosis that continued to be subjected to bloodletting, a 'control' group of 38 patients with similar nosographic characteristics. The retrospective assessment has been focused on the following parameters: hematocrit, levels of blood ferritin, number of treatment procedures, length of intervals between a treatment and another. We also evaluated the costs of treatment.
Results
The mean number of treatment / year procedures was significantly lower for patients treated with erytrocyte- apheresis compared to those treated with bloodletting. The average time interval between two consecutive treatments is a result of 2.3 times longer for the erytrocyte- apheresis compared to bloodletting. The interval between two consecutive procedures of erytrocyte- apheresis has shown a tendency to a progressive increase in the longer time interval of time between a drain and the other. The average annual cost of treatment with erytrocyte- apheresis was about twice compared to those of bloodletting.
Conclusion
The erytrocyte- apheresis reduced, in our experience, significantly the number of treatment procedures rather than the bloodletting. We believe that, where there is easily available the acces to the extracorporeal circulation for cell separation, the erytrocyte- apheresis procedure could become the treatment of choice for patients suffering from hemochromatosis.
Session topic: E-poster
Keyword(s): Apheresis
{{ help_message }}
{{filter}}